

H. Lundbeck A/S

Ottiliavej 9
DK-2500 Valby, Copenhagen
CVR number: 56759913
LEI code: 5493006R4KC2OI5D3470

Tel +45 36 30 13 11

E-mail investor@lundbeck.com
www.lundbeck.com



Corporate Release

Thomas Gibbs to join Lundbeck as Executive Vice President and Head of Lundbeck in the United States

Valby, Denmark, January 12, 2023 - H. Lundbeck A/S (Lundbeck) is pleased to announce Thomas (Tom) Gibbs is appointed as Executive Vice President and Head of Lundbeck in the United States. He will also be a member of Lundbeck's Executive Management. Tom will be based in Lundbeck's U.S. head office in Chicago, Illinois, and assume the role no later than end of February 2023.

Tom joins Lundbeck from Vectura Inc., a pharmaceutical company, where he currently serves as Chief Executive Officer and Global Business Leader. In this role, he established an organization to advance the development and commercialization of their inhaled therapeutics portfolio.

Prior to his role at Vectura, Tom held several Chief Commercial Officer roles, developing Commercial strategy and overseeing execution for U.S., Canadian and European markets at pharmaceutical companies with strong central nervous system (CNS) franchises, including a role as Chief Commercial Officer at Sunovion. He has also served as Head of General Medicines in the U.S. for Takeda.

Tom holds a B.S. in Economics and an MBA from the Wharton School, University of Pennsylvania.

"We look forward to having Tom join Lundbeck and the Executive Management team. He brings extensive experience in neuroscience as well as his success in launching and growing brands across large and small pharmaceutical companies in multiple therapeutic categories. This, combined with his empowering approach to leadership, global mindset, in-depth knowledge of the pharmaceutical industry and strong experience in neuroscience will continue to accelerate the growth and development of Lundbeck and add additional insights to our overall strategic direction as part of the EM," said Deborah Dunsire, CEO of Lundbeck.

"Given the size and impact of the U.S. market for Lundbeck, the importance of the two launches we have there in 2023, as well as our ambitions to grow through both internal and external innovation, we will benefit from an Executive Management leader located in Chicago to lead the team, and Lundbeck overall, through these priorities. I'd like to thank Jacob Tolstrup for his leadership of the U.S. organization over the past year. He has decided to remain based in Valby and focus his efforts as Executive Vice President for Commercial Operations in the rest of the world and Strategic Marketing moving forward," she continued.



Lundbeck contacts

Investors:

Palle Holm Olesen

Vice President,

Investor Relations

PALO@lundbeck.com

+45 30 83 24 26

Media:

Juliane Lenzner

Vice President,

Head of Communications & Public Affairs

JULZ@lundbeck.com

+45 30 83 23 97

About H. Lundbeck A/S

Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best. We are committed to fighting stigma and discrimination against people living with brain diseases and advocating for broader social acceptance of people with brain health conditions. Our research programs tackle some of the most complex challenges in neuroscience, and our pipeline is focused on bringing forward transformative treatments for brain diseases for which there are few, if any therapeutic options.

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Instagram ([h_lundbeck](https://www.instagram.com/h_lundbeck)), Twitter at [@Lundbeck](https://twitter.com/Lundbeck) and via LinkedIn.



Safe Harbor/Forward-Looking Statements

This corporate release contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe", "anticipate", "expect", "estimate", "intend", "plan", "project", "will be", "will continue", "will result", "could", "may", "might", or any variations of such words or other words with similar meanings. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements.

Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Factors that may affect future results include, among others, interest rate and currency exchange rate fluctuations, delay or failure of development projects, production or distribution problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

The forward-looking statements in this document and oral presentations made on behalf of Lundbeck speak only as at the date of this presentation. Lundbeck does not undertake any obligation to update or revise forward-looking statements in this presentation or oral presentations made on behalf of Lundbeck, nor to confirm such statements to reflect subsequent events or circumstances after the date of the presentation or in relation to actual results, unless otherwise required by applicable law or applicable stock exchange regulations.